Ali Siam is Chief Business Officer at Celmatix, where he leads business and strategy development. Ali brings a rare combination of strategic planning and operating experience across functional areas in healthcare and the life sciences. Prior to joining Celmatix, he led corporate strategy, R&D prioritization, portfolio strategy, and due diligence engagements for small to large pharmaceutical, diagnostic, healthcare services, biotech, and institutional investor clients across therapeutic areas as a team leader at L.E.K. Consulting. He also led collaborations with innovators in an atypical modalities-focused partnering team at AbbVie, in addition to roles in Market Access and Marketing across Oncology, Immunology, Infectious Disease, Neuroscience, and Metabolics. Ali also has strategic marketing and R&D experience from his time at Johnson & Johnson and Boston Scientific, and holds an MBA from Boston College and a BS in Mechanical Engineering from Northeastern University.